 Harvard’s
Paul M. Ridker on C-Reactive Protein
It
took 30 years for researchers to agree that lower serum
cholesterol would reduce the risk of heart disease, but
they seem to be moving considerably faster when it comes
to inflammation. In the past five years, cardiologist
Paul M. Ridker and his colleagues at Harvard Medical
School's Brigham and Women's Hospital in Boston have
managed to amass a compelling amount of data suggesting
that a marker for inflammation, known as the C-reactive
protein (CRP), is a potent risk factor for
cardiovascular disease, and that drugs that reduce CRP
levels will reduce heart-disease risk, as well.
The extent to which this idea is
catching fire with medical researchers is made manifest
by Ridker's phenomenal citations. By the summer of 2001... |
 |
|
.
